Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancer.

doi:10.1038/nm.4507

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancer.

Nature medicine - 1 May 2018

Nair Amritha, Chung Hsiang-Ching, Sun Tingting, Tyagi Siddhartha, Dobrolecki Lacey E, Dominguez-Vidana Rocio, Kurley Sarah J, Orellana Mayra, Renwick Alexander, Henke David M, Katsonis Panagiotis, Schmitt Earlene, Chan Doug W, Li Hui, Mao Sufeng, Petrovic Ivana, Creighton Chad J, Gutierrez Carolina, Dubrulle Julien, Stossi Fabio, Tyner Jeffrey W, Lichtarge Olivier, Lin Charles Y, Zhang Bing, Scott Kenneth L, Hilsenbeck Susan G, Sun Jinpeng, Yu Xiao, Osborne C Kent, Schiff Rachel, Christensen James G, Shields David J, Rimawi Mothaffar F, Ellis Matthew J, Shaw Chad A, Lewis Michael T, Westbrook Thomas F

Abstract excerpt

Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer diagnosed in more than 200,000 women each year and is recalcitrant to targeted therapies. Although TNBCs harbor multiple hyperactive receptor tyrosine kinases (RTKs), RTK inhibitors have been largely ineffective in TNBC patients thus far. We developed a broadly effective therapeutic strategy for TNBC that is based on combined...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Survival

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Crizotinib

Share to Mice, Nude

Share to Receptor Protein-Tyrosine Kinases

Share to Receptors, Cell Surface

Share to Sunitinib

Share to Triple Negative Breast Neoplasms

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 29578538
DOI: 10.1038/nm.4507
PMCID: PMC6675908

Genes

PTPN12
MET
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancer.PMID 29578538Read ↗

Activation of multiple proto-oncogenic tyrosine kinases in breast cancer via loss of the PTPN12 phosphatase.Semantic proximity Read ↗

Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, Is Highly Active Against Triple-Negative Breast CancerSemantic proximity Read ↗

The Tyrosine Kinome Dictates Breast Cancer Heterogeneity and Therapeutic ResponsivenessSemantic proximity Read ↗

Receptor tyrosine kinases (RTKs) in breast cancer: signaling, therapeutic implications and challengesSemantic proximity Read ↗

Cooperative regulation of coupled oncoprotein synthesis and stability in triple-negative breast cancer by EGFR and CDK12/13Semantic proximity Read ↗

TCR-Engineered T Cells Directed against Ropporin-1 Constitute a Safe and Effective Treatment for Triple-Negative Breast CancerSemantic proximity Read ↗

Targeted MDM2 Degradation Reveals a New Vulnerability for p53-Inactivated Triple-Negative Breast CancerSemantic proximity Read ↗

Potential therapeutic targets of the JAK2/STAT3 signaling pathway in triple-negative breast cancerSemantic proximity Read ↗

Pharmacological profiling of kinase dependency in cell lines across triple-negative breast cancer subtypes.Semantic proximity Read ↗

Global phosphotyrosine survey in triple-negative breast cancer reveals activation of multiple tyrosine kinase signaling pathways.Semantic proximity Read ↗

Development of therapeutic approaches to 'triple negative' phenotype breast cancer.Semantic proximity Read ↗

TCR-engineered T-cells directed against Ropporin-1 constitute a safe and effective treatment for triple-negative breast cancer in near-clinical modelsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.